Cyanotic Congenital Heart Disease Clinical Trial
— bluesensorOfficial title:
A Study About Accuracy of Pulse Oximeter With Hypoxemic Measurements (Blue Sensor) in Children With Cyanotic Congenital Heart Disease
| Verified date | April 2018 |
| Source | Seoul National University Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
A study about accuracy of pulse oximeter with hypoxemic measurements (Blue sensor, Masimo, Irvine, CA, USA) in children with cyanotic congenital heart disease
| Status | Completed |
| Enrollment | 280 |
| Est. completion date | December 2017 |
| Est. primary completion date | March 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A to 18 Years |
| Eligibility |
Inclusion Criteria: - clinical diagnosis of cyanotic congenital heart disease - weight 2.5kg to 30kg - undergoing general anesthesia - preoperative SpO2<97% Exclusion Criteria: |
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | Seoul National University Hospital | Seoul |
| Lead Sponsor | Collaborator |
|---|---|
| Seoul National University Hospital |
Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | accuracy of pulse oximetry using blue sensor | Each arterial blood gas sample and pulse oximeter oxygen saturation (SpO2) from blue sensor pulse oximetry are simultaneously obtained if the SpO2 is <97%. | From the start of anesthetic induction until discharge from hospital, assessed up to 1 week. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02564796 -
Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial
|
Phase 2 | |
| Completed |
NCT01018472 -
Probiotics in Infants With Cyanotic Congenital Heart Disease
|
N/A | |
| Completed |
NCT05800691 -
Predicting Factors for Mortality in Congenital Heart Disease Patients After Shunt Procedure in Developing Country.
|
||
| Recruiting |
NCT04891081 -
Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease
|
||
| Completed |
NCT01426542 -
Preventing Brain Injury in Infants With Congenital Heart Disease
|
Phase 1 | |
| Completed |
NCT03678909 -
Cardiac Biomarkers in Patients With Single Ventricle Physiology
|
||
| Completed |
NCT04125550 -
Propofol vs Sevoflurane in Cyanotic Congenital Heart Disease
|
Phase 4 |